Mateos M-V, Dimopoulos MA, Cavo M, et al. Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE). ASH 59th Annual Meeting & Exhibition, abstract LBA-4.
CD47-remmer Hu5F9-G4 plus rituximab bij non-hodgkinlymfoom
jan 2019 | Lymfoom